Marlen Pfisterer, Anton Teetzmann, Sina Vetter, Joscha Baeßler, Lena Schreckenberger, Judith Zaiser, Manuel Stenger, Patrick Bach
{"title":"CBD attenuates amygdala response to negative emotional stimuli in individuals with alcohol use disorder - a randomized controlled trial.","authors":"Marlen Pfisterer, Anton Teetzmann, Sina Vetter, Joscha Baeßler, Lena Schreckenberger, Judith Zaiser, Manuel Stenger, Patrick Bach","doi":"10.1007/s00213-025-06860-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>Negative affect is a key factor in Alcohol Use Disorder (AUD) associated with craving and relapse risk that is insufficiently treated by approved medications. Cannabidiol (CBD) has shown promising effects on negative affect, indicating its potential for addressing the neurocircuitry underlying negative affect in AUD.</p><p><strong>Objectives: </strong>This study investigates CBD's effects on neural response to negative emotional stimuli and subjective alcohol craving in individuals with AUD.</p><p><strong>Methods: </strong>We conducted the first neuroimaging study investigating CBD's effects on neural responses to negative emotional stimuli and craving in AUD. The study was designed as two armed, 1:1 randomized, double blind, parallel group neuroimaging trial, enrolled N = 28 individuals with AUD. It compared the effects of 800 mg oral CBD versus matched Placebo (PLC) on blood oxygenated level dependent (BOLD) response in the amygdala during a validated emotion processing task and explored associations with CBD plasma levels and subjective alcohol craving.</p><p><strong>Results: </strong>CBD versus PLC attenuated bilateral amygdala reactivity to angry and fearful faces (p<sub>FWE</sub> <.05, small volume corrected), while CBD showed no effect on amygdala activation during the presentation of neutral shape stimuli. Amygdala response to negative emotional stimuli correlated positively with the extent of subjective alcohol craving (r<sub>Left Amygdala</sub> =.52, p<sub>FDR</sub> =.01; r<sub>Right Amygdala</sub> =.52, p<sub>FDR</sub> =.01) and negatively with CBD plasma levels (r<sub>Left Amygdala</sub> = -.68, p<sub>FDR</sub> = 0.002; r<sub>Right Amygdala</sub> = -.65, p<sub>FDR</sub> = 0.002).</p><p><strong>Conclusion: </strong>In summary, CBD's effects on amygdala reactivity to negative emotional stimuli in individuals with AUD support CBD's potential for modulating emotion-processing circuits in AUD and CBD's treatment potential for craving and relapse driven by negative affective states.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06860-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Rationale: Negative affect is a key factor in Alcohol Use Disorder (AUD) associated with craving and relapse risk that is insufficiently treated by approved medications. Cannabidiol (CBD) has shown promising effects on negative affect, indicating its potential for addressing the neurocircuitry underlying negative affect in AUD.
Objectives: This study investigates CBD's effects on neural response to negative emotional stimuli and subjective alcohol craving in individuals with AUD.
Methods: We conducted the first neuroimaging study investigating CBD's effects on neural responses to negative emotional stimuli and craving in AUD. The study was designed as two armed, 1:1 randomized, double blind, parallel group neuroimaging trial, enrolled N = 28 individuals with AUD. It compared the effects of 800 mg oral CBD versus matched Placebo (PLC) on blood oxygenated level dependent (BOLD) response in the amygdala during a validated emotion processing task and explored associations with CBD plasma levels and subjective alcohol craving.
Results: CBD versus PLC attenuated bilateral amygdala reactivity to angry and fearful faces (pFWE <.05, small volume corrected), while CBD showed no effect on amygdala activation during the presentation of neutral shape stimuli. Amygdala response to negative emotional stimuli correlated positively with the extent of subjective alcohol craving (rLeft Amygdala =.52, pFDR =.01; rRight Amygdala =.52, pFDR =.01) and negatively with CBD plasma levels (rLeft Amygdala = -.68, pFDR = 0.002; rRight Amygdala = -.65, pFDR = 0.002).
Conclusion: In summary, CBD's effects on amygdala reactivity to negative emotional stimuli in individuals with AUD support CBD's potential for modulating emotion-processing circuits in AUD and CBD's treatment potential for craving and relapse driven by negative affective states.
期刊介绍：
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
